Why did GeoVax (GOVX) stock rise 60% today?

The monkeypox debate is heating up. And no matter where individuals fall on the spectrum, it’s clear that this painful, but rarely fatal, disease is the one experts are trying to get ahead of. Accordingly, today’s impressive move in GeoVax (NASDAQ:GOUVX) is perhaps not surprising. Indeed, GOVX stock has been racing lately, rising another 60% during today’s session.

Indeed, GeoVax is one of the few companies to produce a vaccine targeting monkeypox. As a comrade InvestorPlace contributor Larry Ramer points out in a recent article that “GeoVax’s vaccines have been validated and registered for [the] prevention of monkeypox virus infection. For those worried about this outbreak, that’s a good thing.

Indeed, it seems that people in San Francisco and New York are increasingly worried about monkeypox. So much so that yesterday, San Francisco and New York State became two regions to officially declare monkeypox a local health emergency. The aim is to strengthen the preparedness of these regions, as the demand for vaccines increases.

Let’s see what investors should think of this news.

Is GOVX Stock a Buy after Impressive Rally?

Certainly, there are a number of positive, forward-looking catalysts on the back of GOVX stock. Should vaccine demand remain high, there is a significant potential market for GeoVax’s vaccines.

Also, with the company expected to release its second quarter results next week, more fireworks could be on the table for this stock. As the print nears, investors seem confident that positive feedback could lift this stock even higher.

That said, it’s worth putting this rally into context. This stock is now a 5-bagger in the space of a week. It’s an incredible short-term run, and if investors feel any hint of selling pressure, it’s clear this stock could have a long way to go. As a result, I think GOVX stocks could be both the best momentum play and riskiest stocks, simultaneously, right now.

As of the date of publication, Chris MacDonald had (neither directly nor indirectly) any position in the securities mentioned in this article. The opinions expressed in this article are those of the author, subject to InvestorPlace.com publishing guidelines.